First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours by Ameratunga, Malaka et al.
ARTICLE
Clinical Study
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ODM-207 in patients with selected solid tumours
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Amir Snapir7,10 and Johann S de Bono1
BACKGROUND: Bromodomain and extra-terminal domain (BET) proteins are reported to be epigenetic anti-cancer drug targets.
This first-in-human study evaluated the safety, pharmacokinetics and preliminary anti-tumour activity of the BET inhibitor ODM-207
in patients with selected solid tumours.
METHODS: This was an open-label Phase 1 study comprised of a dose escalation part, and evaluation of the effect of food on
pharmacokinetics. ODM-207 was administered orally once daily. The dose escalation part was initiated with a dose titration in the
initial cohort, followed by a 3+ 3 design.
RESULTS: Thirty-five patients were treated with ODM-207, of whom 12 (34%) had castrate-resistant prostate cancer. One dose-
limiting toxicity of intolerable fatigue was observed. The highest studied dose achieved was 2mg/kg due to cumulative toxicity
observed beyond the dose-limiting toxicity (DLT) treatment window. Common AEs included thrombocytopenia, asthenia, nausea,
anorexia, diarrhoea, fatigue, and vomiting. Platelet count decreased proportionally to exposure with rapid recovery upon treatment
discontinuation. No partial or complete responses were observed.
CONCLUSIONS: ODM-207 shows increasing exposure in dose escalation and was safe at doses up to 2mg/kg but had a narrow
therapeutic window.
CLINICAL TRIAL REGISTRATION: The clinical trial registration number is NCT03035591.
British Journal of Cancer (2020) 123:1730–1736; https://doi.org/10.1038/s41416-020-01077-z
BACKGROUND
Acetylation of lysine residues on histone tails is associated with open
chromatin and transcriptional activation.1 Bromodomains are a
highly evolutionarily conserved family of proteins responsible for
binding acetylated lysine residues at the amino-terminal tails of
histones.2 The bromodomain and extra-terminal (BET) family (BRD2,
BRD3, BRD4 and BRDT) contain two tandem bromodomains which
bind acetylated lysine residues, facilitating recruitment of transcrip-
tional proteins to chromatin.3 BRD4 localises to promoter and
enhancer regions of chromatin, and functions to regulate RNA-pol II-
mediated elongation and transcription through interactions with the
Mediator complex and pTEFb.4,5 In many tumour types, the efficacy
of BET inhibitors has been attributed to the transcriptional
suppression of genes such as MYC.6 More significantly, evidence
of the oncogenic nature of BRD4 is apparent in the rare and
aggressive tumour known as nut midline carcinoma (NMC), which
occurs as the result of a chromosomal translocation with a resultant
fusion protein of BRD4 with nuclear protein in testis (NUT).7
Although less common, the BRD3-NUT fusion protein may confer a
better prognosis whilst still potentially responding to therapeutic
inhibition with BET inhibitors.8,9 Importantly, there is evidence that
preclinical activity of various BET inhibitors in various tumour types
can be both MYC dependent6 and MYC independent.10 Conse-
quently, the BET family of proteins are a promising candidate for
anti-cancer therapy.
Several small molecule BET inhibitors, predominantly structu-
rally related to JQ1, are in clinical development and have shown
some preliminary clinical activity in NMC and lymphoma.11–14
These studies showed BET inhibition strongly correlated with
decreasing platelet count.13,14 ODM-207, a novel small molecule
that is structurally unrelated to JQ1, is a highly potent pan-BET
inhibitor that has shown preclinical evidence of tumour growth
inhibition in breast cancer and in leukaemia and prostate cancer
xenograft models.15–18 ODM-207 has shown minimal cross-
reactivity with non-BET family bromodomains.
Here, we describe the first-in-human Phase 1 study designed to
investigate the safety, pharmacokinetics and maximum tolerated
dose (MTD) of ODM-207 in patients with advanced malignancies.
Platelet count was chosen as a pharmacodynamic biomarker
based on the observed robust correlation between BET inhibitor
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This was a Phase 1–2, multicentre, non-randomised, open-label,
dose-escalation study of ODM-207 (NCT03035591, Orion Corpora-
tion) in patients with selected solid tumours. The primary
objectives were to determine the safety and tolerability, dose-
limiting toxicities (DLT), and maximum tolerated dose (MTD) of
ODM-207. The secondary objectives of the study were to
characterise the pharmacokinetics of ODM-207 and its main
metabolite, to evaluate the effects of food on bioavailability and to
generate preliminary evidence of target inhibition and anti-
tumour activity.
The study design contained two parts: (1) dose escalation in
patients with advanced solid tumours with an innovative single
dose accelerated titration procedure in the first cohort (1A), (2)
evaluation of food effect on bioavailability (1B). The single-dose
accelerated titration procedure in the first cohort involved
comparison of measured pharmacokinetic parameters in the first
cohort of patients against preclinical models to evaluate whether
exposure was within the target range. If the measured exposure
was outside the target range (below or above), the protocol
allowed for dose adjustment. Dose escalation was performed
using a traditional 3+ 3 schedule. The food effect cohort involved
a single fasted dose (overnight fasting, food allowed 4-h after
dosing); after a washout period ODM-207 was given after a light
breakfast (200–300 kcal of which 50–100 kcal from fat). The
relevant national authorities provided regulatory approval and
local institutional review boards approved the protocol. All study
procedures were conducted in accordance with the Declaration of
Helsinki and good clinical practice. All patients provided written
informed consent.
Patients and drug administration
Patients in the dose escalation part received oral ODM-207 once
daily in a 28-day cycle at a starting dose of a 50 mg tablet daily
under fed conditions. The starting dose was chosen as it was
reasonably expected to be both pharmacologically active and safe
and tolerable. The target exposure for the starting dose was
estimated from exposures observed in pre-clinical anti-tumour
activity and safety studies. The estimated human dose required
was predicted by both human equivalent dose calculations and
physiologically-based pharmacokinetic modelling. A single dose
titration procedure was performed in the first cohort of patients to
confirm that exposure of ODM-207 in humans corresponded with
the pre-defined target exposure based on non-clinical data. The
starting dose provided plasma exposure that was in the target
range. Therefore, no further dose titration in the first cohort was
pursued (Fig. S1). Treatment was taken in the ambulatory setting,
except for hospital admissions required for pre-specified study-
related procedures.
Eligible patients had histologically confirmed NMC, high-grade
serous ovarian cancer, HER2 negative breast cancer, castrate-
resistant prostate cancer, small cell lung cancer, non-small cell
lung cancer, melanoma, non-Hodgkin lymphoma, sarcoma or any
other tumour predicted to have a significantly higher likelihood of
response to ODM-207 (such as MYC amplified tumours), with no
effective standard therapy available. Patients had to have ECOG
performance status ≤ 1, adequate haematopoietic, renal, hepatic
and coagulation function, life expectancy >12 weeks and needed
a washout period from prior anti-cancer therapy.
Procedures and safety assessments
Safety was assessed at baseline, continuously during treatment
and for 28 days following cessation of ODM-207. The National
Cancer Institute Common Terminology Criteria for Adverse Events
(version 4.03) were used to grade treatment-emergent adverse
events (AEs).19 DLTs, defined as AEs related to ODM-207 that
occurred within the first 28 days (cycle 1), included grade 4
neutropaenia lasting more than seven days, febrile neutropaenia,
grade 3 thrombocytopaenia with grade 3 bleeding or grade 4
thrombocytopaenia lasting more than three days, treatment
interruption of 14 days, persistent grade 3 gastrointestinal toxicity
despite optimal medical intervention, grade 3 liver function
abnormalities lasting more than seven days. The MTD was defined
at the highest dose at which <33% of patients experienced DLTs
during cycle 1 within a cohort. Response was assessed using
RECIST 1.1 for patients with advanced solid tumours,20 Prostate
Cancer Working Group 3 criteria (PCWG3) for castrate-resistant
prostate cancer21 and Lugano criteria for non-Hodgkin lym-
phoma.22 Blood samples were taken at nine time points on initial
dosing, after two weeks of dosing and before dosing in all follow
up visits to establish the pharmacokinetic profile (maximum
concentration, maximum time, area under the plasma
concentration-time curve, volume of distribution, clearance and
half-life, and minimum concentration at long term steady state) of
ODM-207.
Statistical analyses
Safety analyses included all patients who received any doses of
treatment. Efficacy evaluation was performed on all patients who
received two or more cycles of treatment (≥8 weeks). Data points
were excluded from relevant pharmacokinetic and platelet count
analyses if samples were taken when the patient was on treatment
interruption or within 3 days after resumption of treatment. Three
levels of exposure (low, mid, high) were defined based on pre-
clinical pharmacological in-house studies about ODM-207 and
observed effects of ODM-207 on count of platelets. Pre-dose total
exposure of <3500 ng/mL was not expected to have significant
BET inhibition effect and a level of ≥5000 ng/mL was expected to
confer BET inhibition.









Number of patients 21 (60) 14 (40) 35 (100)
Age, years, median
(range)
63 (31–78) 54 (17–74) 60 (17–78)
Sex
Female 9 (43) 5 (36) 14 (40)
Male 12 (57) 9 (64) 21 (60)
Cancer type
CRPC 8 (38) 4 (29) 12 (34)
Melanoma 2 (10) 3 (21) 5 (14)
NMC 0 (0) 4 (29) 4 (11)
ER+ BC 4 (19) 0 (0) 4 (11)
Other 7 (33) 3 (21) 10 (29)
ECOG PS
0 10 (48) 3 (21) 13 (37)
1 11 (52) 11 (79) 22 (63)
≥3 Prior lines of
antineoplastic
treatment
19 (90) 10 (71) 29 (83)
CRPC castration resistant prostate cancer, NMC NUT midline carcinoma, ER
+ BC oestrogen receptor positive breast cancer, PS performance status.
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Between 22 December 2016 and 10 May 2019, 36 patients were
enrolled, and 35 patients were treated at doses ranging from 50
mg to 205 mg corresponding with a range of 0.6–2.0 mg/kg.
After a dose-limiting toxicity of fatigue was observed in one
subject in cohort 1A-2 (100 mg), a decision was made to
change the dosing regimen to weight-based dosing due to a
wide range of exposure and assumed narrow therapeutic range.
Dose escalation continued with mg/kg-based dosing up to
the level of 2 mg/kg. This dose level was determined to be the
MTD based upon observed adverse events, although further
DLTs were not observed. The demographic information is
shown in Table 1. Of the 35 treated patients, 12 (34%) had
castrate-resistant prostate cancer (CRPC), 5 (14%) had mela-
noma, 4 (11%) had NMC, 4 (11%) had oestrogen receptor
positive breast cancer (ER+ BC) and 10 (29%) had other tumour
types. Median age was 60 years (range 17–78 years). Treatment
discontinuation occurred due to disease progression in 28 (80%)
patients, due to AEs in 5 (14%) patients and 2 (6%) for other
reasons.
Dose escalation
O 36 patients enrolled in the study, 35 were evaluable for safety
(one patient did not receive ODM-207 due to rapidly deteriorating
performance status). Based on the pharmacokinetic results from
single-dose titration in the first cohort of patients no adjustment
was required for the starting dose. One patient receiving a dose of
100mg (1.9 mg/kg) experienced a DLT of intolerable grade 3
fatigue which was attributable to ODM-207 and this cohort (1A-2)
was expanded. Although dose escalation continued up to the
dose of 2 mg/kg without further dose-limiting toxicities, the safety
monitoring board determined this to be the maximum tolerated
dose due to ongoing intolerable fatigue and nausea, necessitating
dose reduction and/or treatment discontinuation beyond the DLT
period at this dose level. At the dose level of 2 mg/kg, five patients
out of six had AEs resulting in dosing interruption and of these
two patients required dose reductions and one discontinued the
study. The dose-limiting toxicities and grade 3 adverse events are
shown in Table 2.
Safety
Overall 31 (89%) patients experienced a treatment-related AE.
Treatment emergent related AEs, which occurred in a frequency of
>10% of patients and/or of grade 3 severity are shown in Table 3.
There were five deaths on study, all of which were considered not
related to ODM-207 (one patient died of bowel obstruction, two of
respiratory distress and two of disease progression). Common AEs
included nausea (66%), thrombocytopaenia (51% of patients
reported any grade), anorexia (49%), fatigue (43%), diarrhoea
(40%), vomiting (40%), headache (37%) and weight loss (23%).
Most common treatment-related grade ≥3 adverse events
included thrombocytopaenia (14.3%), nausea (8.6%) and fatigue
(5.7%).
Pharmacokinetics
Analysis of plasma pharmacokinetics showed slow absorption and
elimination of ODM-207 with a median time to peak concentration
between 2 and 6 h. Mean ODM-207 AUC(0-t) increased between
day 1 and day 15 of dosing by 3.4-fold (n= 28, 95% CI 2.9, 3.8).
Cohort mean total plasma concentrations on day 1 and day 15
(steady state) are presented in Fig. 1a. Plasma exposure to ODM-
207 (AUC0-24) under fed condition was higher 1.5-fold than under
fasting condition (Fig. 1b). The main metabolite is a demethylation
product of ODM-207. The metabolite/parent ratio based in AUC(0-t)
was 0.1–0.2 on day 1 and 0.1–0.5 on day 15.
Pharmacodynamics
As was shown with other BET inhibitors,13,14,23 a strong correlation
was observed between ODM-207 plasma exposure and changes in
platelet count over time. Prompt recovery of platelet count upon
treatment interruption was observed (Fig. 2).
Anti-tumour activity
Of the 27 patients with RECIST tumour response data, 21 were
evaluable (completing ≥ 8 weeks of treatment). None had a partial
Table 2. DLTs and grade 3 adverse events.
1A-1
0.6 mg/kga (n= 3)
1A-2
1.3 mg/kga (n= 7)
1A-3




1.1 mg/kg (n= 10)
1B-2
1.4 mg/kg (n= 4)
Total (n= 35)
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
SAEs 2 (29) 2 (40) 3 (50) 3 (30) 4 (100) 14 (40)
DLTs 1 (14) 1 (2.9)
Related SAEs 2 (33) 1 (25) 3 (8.6)
Grade ≥ 3 AEs 3 (43) 2 (40) 4 (67) 6 (60) 4 (100) 19 (54)
AEs leading to study discontinuation 1 (33) 2 (40) 1 (17) 3 (30) 2 (50) 9 (26)
AEs leading to dose reduction 2 (33) 1 (10) 1 (25) 4 (11)
AEs leading to dosing interruption 2 (67) 4 (57) 2 (40) 5 (83) 4 (40) 2 (50) 19 (54)
aCohorts 1A-1 and 1A-2 were given the doses 50 and 100mg, respectively, presented in Table 2 as cohort average in mg/kg. The range of doses in cohort 1A-1
was 0.1–0.7 and in 1A-2 was 0.9–1.9 mg/kg.
Table 3. Related AEs.
Total (n= 35)
GRADE 1 GRADE 2 GRADE 3 GRADE 4
System n (%) n (%) n (%) n (%)
Haematologic
Thrombocytopaenia 15 (43) 8 (23) 4 (11) 1 (2.9)
Gastrointestinal
Diarrhoea 9 (26) 5 (14)
Nausea 13 (37) 4 (11) 3 (8.6)
Vomiting 7 (20) 3 (8.6)
General
Asthenia 3 (8.6) 3 (8.6)
Fatigue 9 (26) 6 (17) 2 (5.7)
Decreased appetite 12 (34) 8 (23)
Weight loss 4 (11) 1 (2.9) 1 (2.9)
Nervous system
Dysgeusia 4 (11) 3 (8.6)
Headache 7 (20) 3 (8.6)
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or complete response (PR, CR). Six patients (29%) had stable
disease (SD), 9 (43%) had progressive disease (PD), and 6 (29%)
had non-CR/non-PD (non-measurable disease) as their best
response. Eight patients (38%) had either SD or non-CR/non-PD
at 16 weeks. The median (range) duration of SD was 16.3
(8.0–23.0) weeks. One out of four patients with NMC had SD as
their best response, the other patients had clinical progression
prior to their first disease assessment. The median progression-
free survival was 2.2 months (range 0.5–9.7 months). Duration on
treatment, ongoing RECIST response and reason for study
discontinuation by patient’s tumour type are summarised in Fig. 3.
There was no correlation between progression-free survival and
increased exposure. None of the prostate cancer patients showed
decline in PSA below baseline level.
DISCUSSION
The aim of this first-in-human Phase 1 study was to assess the
safety and tolerability of the BET inhibitor ODM-207. The main
dose-limiting adverse events were nausea and fatigue and the
maximal tolerated dose of 2 mg/kg was identified. Other
significant observed toxicities included asthenia and anorexia.
Consistent with other studies of BET inhibitors, reversible
thrombocytopaenia was observed,12,24 which further validates
platelet count as a potential pharmacodynamic marker of on-
target BET inhibition. We could not validate ODM-207’s therapeu-
tic efficacy in NMC because the enrolled patients either
progressed within days of enrolment (3 out of 4) or had very
low ODM-207 plasma exposure (1 patient). None of these patients
developed thrombocytopaenia. Thus, the lack of activity in these
patients reflects inadequate exposure, which when coupled with
an aggressive underlying disease, resulted in rapid disease
progression.
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Fig. 2 Platelet count change over time. Mean platelet change from
baseline (%) by pre-dose ODM-207 exposure (a) and examples of
recovery of platelets upon dosing interruption (b). a Pre-dose
concentration (ng/mL) <3500 (blue triangle), 3500–5000 (orange
circle), and ≥5000 (green diamond). b Dosing interruption (orange
circle) and resumption (green triangle).
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Fig. 1 Pharmacokinetics of ODM-207. Cohort mean concentrations in fed-state on day 1 and day 15 (a), and in fed/fasted state in one cohort
(b). a Cohorts 1A-1 0.6 mg/kg (blue square), Cohort 1A-2 1.3 mg/kg (green circle), Cohort 1A-3 1.5 mg/kg (orange diamond), and Cohort 1A-4
2.0 mg/kg (pink triangle). b Fasted state (blue square) and fed state (green circle).
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A unique aspect of this clinical trial was the novel dose
titration methodology utilised in the first cohort of patients.
Plasma pharmacokinetic parameters were sampled after
single dosing and were evaluated against preclinical models
of exposure, providing confidence regarding the exposure
and pharmacokinetic profiles in humans and mitigating the
risk of inaccurate translations from models to humans and
the risk for too low or too high dose in the first cohort of the
first-in-human study. This methodology is particularly useful for
first-in-human studies in which preclinical confidence in
bioavailability is limited due to significant variability between
models, or as in this case, where a narrow therapeutic window is
expected.
In this study, modelling was performed over a short duration
of 7 days, and also confirmed that exposure in the first cohort
was at target level based on non-clinical data, demonstrating
that rapid pharmacokinetic assessment is possible within a
clinical trial setting whilst minimising the risk of inadequate
exposure to this cohort of patients with advanced cancer.
Although not demonstrated within this trial, this design could
theoretically also reduce the number of dose escalation steps if
dose titration was required, saving unnecessary burden from
patients, either treated with a too low or high dose. Such a
procedure can also significantly decrease development time and
use of resources. In addition, the food-effect cohort included
within this study, robustly demonstrated the association of the
fed state with increased exposure. Overall at the higher dose
levels, exposure was within the range expected for clinical
activity. Target inhibition was confirmed with the consistent
exposure-dependent decrease in platelet count observed across
the study.
Multiple first-in-human studies of BET inhibitors have now been
published, with the majority of compounds being analogues of
JQ1, the first identified BET inhibitor.3 The chemical composition
of ODM-207 is distinct from JQ1 analogues, but notably had
overlapping profile of adverse events with other compounds.12,24
Consistently with other BET inhibitors, treatment-related adverse
events limited dose escalation with most commonly observed AEs
being thrombocytopenia, nausea, fatigue, decreased appetite, and
diarrhoea.
Eight (38% of 21 evaluable patients) had stable disease or non-
CR/non-PD for 16 weeks or more. The lack of significant responses
is consistent with other studies of BET inhibitors, none of which
have observed significant responses in solid tumours.11,12,24 The
results of this study, when contextualised with the results of other
Phase 1 studies of BET inhibitors in solid tumours, convey
evidence of no strong signal of efficacy as a monotherapy in
tumour types other than NMC. Mechanistically, the BET family of
proteins control a diverse array of cellular processes6 and more
preclinical work needs to be done prior to elucidation of the
appropriate clinical context wherein BET inhibitors may be best
utilised.25 The results of this trial herein, and emerging data from
other Phase 1 studies of BET inhibitors in solid tumours, suggest
that achieving a therapeutic window where an anti-tumour effect
can be achieved without undue adverse events due to on-target
effects may be challenging with this class of agents, also making
drug combinations particularly difficult. Nevertheless, the diverse
transcriptional networks impacted by BET inhibition have raised
multiple combination opportunities, the goal being more favour-
able risk/benefit ratios. Of particular interest are combinations
with immune checkpoint inhibitors,26,27 PARP inhibitors,28,29
CDK4/6 inhibitors or similar.30,31
Fig. 3 Duration of treatment and reason for discontinuation by cancer type. CRPC castration-resistant prostate cancer, ER+mBC oestrogen
receptor positive metastatic breast cancer, NMC NUT midline carcinoma, NSCLC non-small cell lung cancer, RSCDS round small cells
desmoplastic sarcoma, CRC colorectal carcinoma, SCLC small cell lung cancer, NHL non-Hodgkin’s lymphoma, SD stable disease, PD
progressive disease, CR complete response, EOS end of study.
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In conclusion, evaluation of the BET inhibitor ODM-207 in this
first-in-human study demonstrated dose proportional exposure
with reversible thrombocytopaenia and in higher dose levels,
fatigue and nausea, consistent with other studies of BET inhibitors.
Strong signal for anti-tumour activity was not observed in patients
with the selected advanced solid tumours.
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